Romiplostim for Injection

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disease, accounting for about 1/3 of all bleeding diseases. It is characterized by isolated peripheral blood platelet count decrease without clear triggering factors. The clinical manifestations are highly heterogeneous, with asymptomatic thrombocytopenia, skin and mucosal bleeding, and in severe cases, visceral bleeding and fatal intracranial hemorrhage. [1] Reducing the risk of bleeding in ITP patients, increasing platelet counts, and improving the quality of life of patients are the most urgent needs for ITP treatment. [2] Glucocorticoids can quickly control the symptoms of ITP, but they have the disadvantages of easy recurrence and large side effects, and cannot be used for a long time. The “Chinese Guidelines for the Diagnosis and Treatment of Primary Immune Thrombocytopenia in Adults (2020 Edition)” recommends platelet-stimulating drugs for the second-line treatment of ITP. [1] Ruilisheng® is the first domestically produced second-generation long-acting TPO receptor agonist developed by Qilu Pharmaceutical. It has the characteristics of rapid clinical onset, low dosing frequency, and good tolerability.